|
Leukemias – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 504 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2012', provides an overview of the Leukemias therapeutic pipeline. This report provides information on the therapeutic developme.....
Introduction Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2012', provides an overview of the Leukemias therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemias. 'Leukemias - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Leukemias. - A review of the Leukemias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Leukemias pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Leukemias. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Leukemias pipeline depth and focus of Leukemias therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 17 Introduction 18 Global Markets Direct Report Coverage 18 Leukemias Overview 19 Therapeutics Development 20 An Overview of Pipeline Products for Leukemias 20 Leukemias Therapeutics under Development by Companies 22 Leukemias Therapeutics under Investigation by Universities/Institutes 35 Late Stage Products 54 Comparative Analysis 54 Mid Clinical Stage Products 55 Comparative Analysis 55 Early Clinical Stage Products 56 Comparative Analysis 56 Discovery and Pre-Clinical Stage Products 57 Comparative Analysis 57 Leukemias Therapeutics – Products under Development by Companies 58 Leukemias Therapeutics – Products under Investigation by Universities/Institutes 79 Companies Involved in Leukemias Therapeutics Development 173 Bristol-Myers Squibb Company 173 Genzyme Corporation 174 Johnson & Johnson 175 Boehringer Ingelheim GmbH 176 F. Hoffmann-La Roche Ltd. 177 Kyowa Hakko Kirin Co., Ltd. 178 Abbott Laboratories 179 Amgen Inc. 180 Sanofi-Aventis 181 AstraZeneca PLC 182 Eli Lilly and Company 183 Athersys, Inc. 184 GlaxoSmithKline plc 185 Seattle Genetics, Inc. 186 Genentech, Inc. 187 Gilead Sciences, Inc. 188 Daiichi Sankyo Company, Ltd 189 medac GmbH 190 Merck & Co., Inc. 191 Emergent BioSolutions Inc. 192 Lentigen Corporation 193 Micromet, Inc. 194 Gamida Cell Ltd. 195 Generex Biotechnology Corporation 196 Albany Molecular Research, Inc. 197 Celltrion, Inc. 198 Bio-Path Holdings, Inc. 199 BioSante Pharmaceuticals, Inc. 200 Aldagen, Inc. 201 ZIOPHARM Oncology, Inc. 202 Millennium Pharmaceuticals, Inc. 203 Novartis AG 204 BioMarin Pharmaceutical Inc. 205 Cephalon, Inc. 206 Eisai Co., Ltd. 207 Glenmark Pharmaceuticals Ltd. 208 Hanmi Pharmaceutical Co Ltd 209 ImmunoGen, Inc. 210 Nippon Shinyaku Co., Ltd. 211 Pfizer Inc. 212 Sunesis Pharmaceuticals, Inc. 213 SuperGen, Inc. 214 Genmab A/S 215 Enzon Pharmaceuticals, Inc. 216 Santaris Pharma A/S 217 Cyclacel Pharmaceuticals Inc. 218 Alfacell Corporation 219 Celgene Corporation 220 Bayer AG 221 Incyte Corporation 222 Geron Corporation 223 Merck KGaA 224 Access Pharmaceuticals, Inc. 225 4SC AG 226 EntreMed, Inc. 227 EpiCept Corporation 228 Hana Biosciences, Inc. 229 Celldex Therapeutics, Inc. 230 AEterna Zentaris Inc. 231 IMMUNOMEDICS, INC 232 InNexus Biotechnology Inc. 233 Ligand Pharmaceuticals Incorporated 234 Ariad Pharmaceuticals, Inc. 235 Lorus Therapeutics Inc 236 Avalon Pharmaceuticals, Inc. 237 MethylGene Inc 238 Northwest Biotherapeutics, Inc. 239 Cleveland BioLabs, Inc. 240 OncoVista Innovative Therapies, Inc. 241 OXiGENE, Inc. 242 Critical Outcome Technologies Inc. 243 Alexion Pharmaceuticals, Inc. 244 BioCryst Pharmaceuticals, Inc. 245 Portola Pharmaceuticals, Inc. 246 CSL Limited 247 Telik, Inc. 248 TopoTarget A/S 249 VioQuest Pharmaceuticals, Inc. 250 CytRx Corporation 251 Pharmacyclics, Inc. 252 Array BioPharma Inc. 253 MorphoSys AG 254 Choongwae Pharma Corp 255 Threshold Pharmaceuticals, Inc. 256 Synta Pharmaceuticals Corp. 257 CrystalGenomics, Inc. 258 BioAlliance Pharma SA 259 Natco Pharma Limited 260 Sareum Holdings plc 261 Clavis Pharma ASA 262 Innate Pharma SA 263 Simcere Pharmaceutical Group 264 Piramal Life Sciences Limited 265 SymBio Pharmaceuticals Limited 266 Cellerant Therapeutics, Inc. 267 InDex Pharmaceuticals AB 268 Debiopharm Group 269 Chroma Therapeutics Ltd. 270 Avaris 271 Ambit Biosciences Corporation 272 Immupharma Plc 273 Memgen, LLC. 274 Actinium Pharmaceuticals, Inc. 275 Abiogen Pharma S.p.A. 276 BioMAS Ltd. 277 ERYtech Pharma 278 ViroStatics, srl 279 Curacyte AG 280 Aquinox Pharmaceuticals Inc. 281 Celator Pharmaceuticals, Inc. 282 Altor BioScience Corporation 283 Ascenta Therapeutics, Inc. 284 TMRC Co., Ltd. 285 Coronado Biosciences, Inc. 286 Arno Therapeutics, Inc. 287 ACT Biotech, Inc. 288 TetraLogic Pharmaceuticals 289 Celentyx Ltd. 290 Semafore Pharmaceuticals, Inc. 291 S*BIO Pte Ltd 292 Deciphera Pharmaceuticals, LLC 293 Xigen SA 294 Affichem 295 Stemline Therapeutics, Inc. 296 Avila Therapeutics, Inc. 297 Proacta, Inc. 298 Cornerstone Pharmaceuticals, Inc. 299 Polyphenon Pharma 300 Advenchen Laboratories, LLC 301 Onconova Therapeutics, Inc 302 MolMed S.p.A. 303 Syndax Pharmaceuticals, Inc. 304 Myriad Pharmaceuticals, Inc. 305 NOXXON Pharma AG 306 Juvaris BioTherapeutics, Inc. 307 Esperance Pharmaceuticals, Inc. 308 Mirna Therapeutics, Inc. 309 Omeros Corporation 310 Trillium Therapeutics Inc. 311 Globeimmune, Inc. 312 SBI Biotech Co., Ltd. 313 PharmaMar, S.A. 314 KaloBios Pharmaceuticals, Inc. 315 Aprea AB. 316 Kinex Pharmaceuticals, LLC 317 OncoImmune, Inc. 318 Cylene Pharmaceuticals, Inc. 319 SymbioTec GmbH 320 GlycoMimetics, Inc. 321 Biothera 322 Nereus Pharmaceuticals, Inc. 323 Advanced Cancer Therapeutics 324 Cellceutix Pharmaceuticals, Inc. 325 Sigma-Tau Pharmaceuticals, Inc. 326 The Alize Pharma Group 327 LFB Biotechnologies, S.A.S.U. 328 Interprotein Corporation 329 EpiZyme, Inc. 330 Targa Therapeutics Corp. 331 Sentinel Oncology Limited 332 Polaris Group 333 ImQuest Life Sciences 334 The Vaccine Company L.P. 335 Immunovative Therapies, Ltd. 336 BerGenBio AS 337 Advancell 338 Leukemias – Therapeutics Assessment 339 Assessment by Monotherapy Products 339 Assessment by Combination Products 340 Assessment by Route of Administration 341 Assessment by Molecule Type 344 Drug Profiles 347 StemEx - Drug Profile 347 Bosutinib - Drug Profile 349 RG7159 - Drug Profile 351 PKC412 - Drug Profile 352 AP24534 - Drug Profile 353 Vosaroxin - Drug Profile 355 Dacogen - Drug Profile 357 AMG-761 - Drug Profile 359 Graspa - Drug Profile 361 Ceplene - Drug Profile 363 Marqibo - Drug Profile 365 Omapro - Drug Profile 367 Omapro - Drug Profile 369 Sapacitabine - Drug Profile 371 ELACYT - Drug Profile 373 Campath + Fludara - Drug Profile 375 TK Cells - Drug Profile 376 Vosaroxin + Cytarabine - Drug Profile 378 Aldesleukin + Ceplene - Drug Profile 380 Treosulfan - Drug Profile 381 PR1 Leukemia Peptide Vaccine + Sargramostim - Drug Profile 382 Revlimid - Drug Profile 383 Flucam - Drug Profile 385 Clolar + Cytarabine - Drug Profile 387 Cytarabine - Drug Profile 389 Arzerra + Fludarabine + Cyclophosphamide - Drug Profile 390 Ofatumumab + Chlorambucil - Drug Profile 392 RG7159 + Chlorambucil - Drug Profile 394 AZD1152 + Cytarabine - Drug Profile 395 Sapacitabine + Decitabine - Drug Profile 397 EZN-2285 - Drug Profile 398 Leukemias Therapeutics – Drug Profile Updates 399 Leukemias Therapeutics – Discontinued Products 419 Leukemias Therapeutics - Dormant Products 433 Leukemias – Product Development Milestones 492 Featured News & Press Releases 492 Appendix 501 Methodology 501 Expert Panel Validation 502 Contact Us 502 Disclaimer 502 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Leukemias, H1 2012 22 Products under Development for Leukemias – Comparative Analysis, H1 2012 23 Number of Products under Development by Companies, H1 2012 25 Number of Products under Development by Companies, H1 2012 (Contd..1) 26 Number of Products under Development by Companies, H1 2012 (Contd..2) 27 Number of Products under Development by Companies, H1 2012 (Contd..3) 28 Number of Products under Development by Companies, H1 2012 (Contd..4) 29 Number of Products under Development by Companies, H1 2012 (Contd..5) 30 Number of Products under Development by Companies, H1 2012 (Contd..6) 31 Number of Products under Development by Companies, H1 2012 (Contd..7) 32 Number of Products under Development by Companies, H1 2012 (Contd..8) 33 Number of Products under Development by Companies, H1 2012 (Contd..9) 34 Number of Products under Development by Companies, H1 2012 (Contd..10) 35 Number of Products under Development by Companies, H1 2012 (Contd..11) 36 Number of Products under Investigation by Universities/Institutes, H1 2012 38 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 39 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 40 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 41 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 42 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 43 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 44 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 45 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 46 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 47 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 48 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 49 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 50 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 51 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 52 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 53 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 54 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 55 Comparative Analysis by Late Stage Development, H1 2012 56 Comparative Analysis by Mid Clinical Stage Development, H1 2012 57 Comparative Analysis by Early Clinical Stage Development, H1 2012 58 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 59 Products under Development by Companies, H1 2012 60 Products under Development by Companies, H1 2012 (Contd..1) 61 Products under Development by Companies, H1 2012 (Contd..2) 62 Products under Development by Companies, H1 2012 (Contd..3) 63 Products under Development by Companies, H1 2012 (Contd..4) 64 Products under Development by Companies, H1 2012 (Contd..5) 65 Products under Development by Companies, H1 2012 (Contd..6) 66 Products under Development by Companies, H1 2012 (Contd..7) 67 Products under Development by Companies, H1 2012 (Contd..8) 68 Products under Development by Companies, H1 2012 (Contd..9) 69 Products under Development by Companies, H1 2012 (Contd..10) 70 Products under Development by Companies, H1 2012 (Contd..11) 71 Products under Development by Companies, H1 2012 (Contd..12) 72 Products under Development by Companies, H1 2012 (Contd..13) 73 Products under Development by Companies, H1 2012 (Contd..14) 74 Products under Development by Companies, H1 2012 (Contd..15) 75 Products under Development by Companies, H1 2012 (Contd..16) 76 Products under Development by Companies, H1 2012 (Contd..17) 77 Products under Development by Companies, H1 2012 (Contd..18) 78 Products under Development by Companies, H1 2012 (Contd..19) 79 Products under Development by Companies, H1 2012 (Contd..20) 80 Products under Investigation by Universities/Institutes, H1 2012 81 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 82 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 83 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 84 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 85 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 86 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 87 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 88 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 89 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 90 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 92 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 93 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 95 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 96 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 97 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 98 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 99 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 100 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 101 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 102 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 103 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 104 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 105 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 106 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 107 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 108 Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 109 Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 110 Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 111 Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 112 Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 113 Products under Investigation by Universities/Institutes, H1 2012 (Contd..31) 114 Products under Investigation by Universities/Institutes, H1 2012 (Contd..32) 115 Products under Investigation by Universities/Institutes, H1 2012 (Contd..33) 116 Products under Investigation by Universities/Institutes, H1 2012 (Contd..34) 117 Products under Investigation by Universities/Institutes, H1 2012 (Contd..35) 119 Products under Investigation by Universities/Institutes, H1 2012 (Contd..36) 120 Products under Investigation by Universities/Institutes, H1 2012 (Contd..37) 121 Products under Investigation by Universities/Institutes, H1 2012 (Contd..38) 122 Products under Investigation by Universities/Institutes, H1 2012 (Contd..39) 123 Products under Investigation by Universities/Institutes, H1 2012 (Contd..40) 124 Products under Investigation by Universities/Institutes, H1 2012 (Contd..41) 125 Products under Investigation by Universities/Institutes, H1 2012 (Contd..42) 126 Products under Investigation by Universities/Institutes, H1 2012 (Contd..43) 127 Products under Investigation by Universities/Institutes, H1 2012 (Contd..44) 128 Products under Investigation by Universities/Institutes, H1 2012 (Contd..45) 129 Products under Investigation by Universities/Institutes, H1 2012 (Contd..46) 130 Products under Investigation by Universities/Institutes, H1 2012 (Contd..47) 131 Products under Investigation by Universities/Institutes, H1 2012 (Contd..48) 132 Products under Investigation by Universities/Institutes, H1 2012 (Contd..49) 133 Products under Investigation by Universities/Institutes, H1 2012 (Contd..50) 134 Products under Investigation by Universities/Institutes, H1 2012 (Contd..51) 135 Products under Investigation by Universities/Institutes, H1 2012 (Contd..52) 136 Products under Investigation by Universities/Institutes, H1 2012 (Contd..53) 137 Products under Investigation by Universities/Institutes, H1 2012 (Contd..54) 138 Products under Investigation by Universities/Institutes, H1 2012 (Contd..55) 139 Products under Investigation by Universities/Institutes, H1 2012 (Contd..56) 140 Products under Investigation by Universities/Institutes, H1 2012 (Contd..57) 141 Products under Investigation by Universities/Institutes, H1 2012 (Contd..58) 142 Products under Investigation by Universities/Institutes, H1 2012 (Contd..59) 143 Products under Investigation by Universities/Institutes, H1 2012 (Contd..60) 144 Products under Investigation by Universities/Institutes, H1 2012 (Contd..61) 145 Products under Investigation by Universities/Institutes, H1 2012 (Contd..62) 146 Products under Investigation by Universities/Institutes, H1 2012 (Contd..63) 147 Products under Investigation by Universities/Institutes, H1 2012 (Contd..64) 148 Products under Investigation by Universities/Institutes, H1 2012 (Contd..65) 149 Products under Investigation by Universities/Institutes, H1 2012 (Contd..66) 150 Products under Investigation by Universities/Institutes, H1 2012 (Contd..67) 151 Products under Investigation by Universities/Institutes, H1 2012 (Contd..68) 152 Products under Investigation by Universities/Institutes, H1 2012 (Contd..69) 153 Products under Investigation by Universities/Institutes, H1 2012 (Contd..70) 154 Products under Investigation by Universities/Institutes, H1 2012 (Contd..71) 155 Products under Investigation by Universities/Institutes, H1 2012 (Contd..72) 156 Products under Investigation by Universities/Institutes, H1 2012 (Contd..73) 157 Products under Investigation by Universities/Institutes, H1 2012 (Contd..74) 158 Products under Investigation by Universities/Institutes, H1 2012 (Contd..75) 159 Products under Investigation by Universities/Institutes, H1 2012 (Contd..76) 160 Products under Investigation by Universities/Institutes, H1 2012 (Contd..77) 161 Products under Investigation by Universities/Institutes, H1 2012 (Contd..78) 162 Products under Investigation by Universities/Institutes, H1 2012 (Contd..79) 163 Products under Investigation by Universities/Institutes, H1 2012 (Contd..80) 164 Products under Investigation by Universities/Institutes, H1 2012 (Contd..81) 165 Products under Investigation by Universities/Institutes, H1 2012 (Contd..82) 166 Products under Investigation by Universities/Institutes, H1 2012 (Contd..83) 167 Products under Investigation by Universities/Institutes, H1 2012 (Contd..84) 168 Products under Investigation by Universities/Institutes, H1 2012 (Contd..85) 169 Products under Investigation by Universities/Institutes, H1 2012 (Contd..86) 170 Products under Investigation by Universities/Institutes, H1 2012 (Contd..87) 171 Products under Investigation by Universities/Institutes, H1 2012 (Contd..88) 172 Products under Investigation by Universities/Institutes, H1 2012 (Contd..89) 173 Products under Investigation by Universities/Institutes, H1 2012 (Contd..90) 174 Bristol-Myers Squibb Company, H1 2012 175 Genzyme Corporation, H1 2012 176 Johnson & Johnson, H1 2012 177 Boehringer Ingelheim GmbH, H1 2012 178 F. Hoffmann-La Roche Ltd., H1 2012 179 Kyowa Hakko Kirin Co., Ltd., H1 2012 180 Abbott Laboratories, H1 2012 181 Amgen Inc., H1 2012 182 Sanofi-Aventis, H1 2012 183 AstraZeneca PLC, H1 2012 184 Eli Lilly and Company, H1 2012 185 Athersys, Inc., H1 2012 186 GlaxoSmithKline plc, H1 2012 187 Seattle Genetics, Inc., H1 2012 188 Genentech, Inc., H1 2012 189 Gilead Sciences, Inc., H1 2012 190 Daiichi Sankyo Company, Ltd, H1 2012 191 medac GmbH, H1 2012 192 Merck & Co., Inc., H1 2012 193 Emergent BioSolutions Inc., H1 2012 194 Lentigen Corporation, H1 2012 195 Micromet, Inc., H1 2012 196 Gamida Cell Ltd., H1 2012 197 Generex Biotechnology Corporation, H1 2012 198 Albany Molecular Research, Inc., H1 2012 199 Celltrion, Inc., H1 2012 200 Bio-Path Holdings, Inc., H1 2012 201 BioSante Pharmaceuticals, Inc., H1 2012 202 Aldagen, Inc., H1 2012 203 ZIOPHARM Oncology, Inc., H1 2012 204 Millennium Pharmaceuticals, Inc., H1 2012 205 Novartis AG, H1 2012 206 BioMarin Pharmaceutical Inc., H1 2012 207 Cephalon, Inc., H1 2012 208 Eisai Co., Ltd., H1 2012 209 Glenmark Pharmaceuticals Ltd., H1 2012 210 Hanmi Pharmaceutical Co Ltd, H1 2012 211 ImmunoGen, Inc., H1 2012 212 Nippon Shinyaku Co., Ltd., H1 2012 213 Pfizer Inc., H1 2012 214 Sunesis Pharmaceuticals, Inc., H1 2012 215 SuperGen, Inc., H1 2012 216 Genmab A/S, H1 2012 217 Enzon Pharmaceuticals, Inc., H1 2012 218 Santaris Pharma A/S, H1 2012 219 Cyclacel Pharmaceuticals Inc., H1 2012 220 Alfacell Corporation, H1 2012 221 Celgene Corporation, H1 2012 222 Bayer AG, H1 2012 223 Incyte Corporation, H1 2012 224 Geron Corporation, H1 2012 225 Merck KGaA, H1 2012 226 Access Pharmaceuticals, Inc., H1 2012 227 4SC AG, H1 2012 228 EntreMed, Inc., H1 2012 229 EpiCept Corporation, H1 2012 230 Hana Biosciences, Inc., H1 2012 231 Celldex Therapeutics, Inc., H1 2012 232 AEterna Zentaris Inc., H1 2012 233 IMMUNOMEDICS, INC, H1 2012 234 InNexus Biotechnology Inc., H1 2012 235 Ligand Pharmaceuticals Incorporated, H1 2012 236 Ariad Pharmaceuticals, Inc., H1 2012 237 Lorus Therapeutics Inc, H1 2012 238 Avalon Pharmaceuticals, Inc., H1 2012 239 MethylGene Inc, H1 2012 240 Northwest Biotherapeutics, Inc., H1 2012 241 Cleveland BioLabs, Inc., H1 2012 242 OncoVista Innovative Therapies, Inc., H1 2012 243 OXiGENE, Inc., H1 2012 244 List of Figures Number of Products under Development for Leukemias, H1 2012 22 Products under Development for Leukemias – Comparative Analysis, H1 2012 23 Products under Development by Companies, H1 2012 24 Products under Investigation by Universities/Institutes, H1 2012 37 Late Stage Products, H1 2012 56 Mid Clinical Stage Products, H1 2012 57 Early Clinical Stage Products, H1 2012 58 Discovery and Pre-Clinical Stage Products, H1 2012 59 Assessment by Monotherapy Products, H1 2012 341 Assessment by Combination Products, H1 2012 342 Assessment by Route of Administration, H1 2012 343 Assessment by Stage and Route of Administration, H1 2012 344 Assessment by Molecule Type, H1 2012 346 Assessment by Stage and Molecule Type, H1 2012 347 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
